argenx SE vs ACADIA Pharmaceuticals Inc.: Annual Revenue Growth Compared

Biotech Giants' Revenue Growth: A Decade of Transformation

__timestamp	ACADIA Pharmaceuticals Inc.	argenx SE
Wednesday, January 1, 2014	120000	4579319.93
Thursday, January 1, 2015	61000	7504448.39
Friday, January 1, 2016	17331000	15466459
Sunday, January 1, 2017	124901000	43793829
Monday, January 1, 2018	223807000	24564806
Tuesday, January 1, 2019	339076000	78116087
Wednesday, January 1, 2020	441755000	44848173
Friday, January 1, 2021	484145000	497277000
Saturday, January 1, 2022	517235000	410746000
Sunday, January 1, 2023	726437000	1226316000

Infusing magic into the data realm

A Tale of Two Biotechs: Argenx SE vs. ACADIA Pharmaceuticals Inc.

In the dynamic world of biotechnology, revenue growth is a key indicator of a company's success and potential. Over the past decade, Argenx SE and ACADIA Pharmaceuticals Inc. have showcased contrasting trajectories in their annual revenue growth. Starting in 2014, ACADIA's revenue was modest, but by 2023, it had grown over 6,000 times, reaching a peak. Meanwhile, Argenx SE, which began with a revenue of approximately $4.6 million in 2014, experienced a staggering growth of over 26,000%, culminating in 2023 with a revenue of $1.23 billion. This remarkable growth highlights Argenx's strategic advancements and market penetration. As the biotech industry continues to evolve, these two companies exemplify the diverse paths to success, driven by innovation and strategic foresight.

Published by

U.S. Securities and Exchange Commission

Source link

sec.gov

Date published

17 Jan 2025